Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | matrix metallopeptidase 7 M10 family | 0.1299 | 0.279 | 0.0968 |
Schistosoma mansoni | subfamily M12A unassigned peptidase (M12 family) | 0.3346 | 1 | 1 |
Onchocerca volvulus | Arrow homolog | 0.097 | 0.1634 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.321 | 0.9521 | 0.9467 |
Loa Loa (eye worm) | hypothetical protein | 0.1363 | 0.3016 | 0.2234 |
Loa Loa (eye worm) | multiple epidermal growth factor-like domains 6 | 0.1079 | 0.2017 | 0.1123 |
Brugia malayi | Calcium binding EGF domain containing protein | 0.1079 | 0.2017 | 1 |
Schistosoma mansoni | egf-like domain protein | 0.097 | 0.1634 | 0.1634 |
Loa Loa (eye worm) | hypothetical protein | 0.1079 | 0.2017 | 0.1123 |
Loa Loa (eye worm) | hypothetical protein | 0.097 | 0.1634 | 0.0698 |
Brugia malayi | Low-density lipoprotein receptor repeat class B containing protein | 0.097 | 0.1634 | 0.8101 |
Loa Loa (eye worm) | hypothetical protein | 0.097 | 0.1634 | 0.0698 |
Loa Loa (eye worm) | AStacin protease | 0.2092 | 0.5584 | 0.5089 |
Echinococcus multilocularis | matrix metallopeptidase 7 (M10 family) | 0.1299 | 0.279 | 0.0968 |
Onchocerca volvulus | Matrilysin homolog | 0.0792 | 0.1006 | 0.616 |
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.1079 | 0.2017 | 0.5 |
Brugia malayi | Fibulin-1 precursor | 0.1079 | 0.2017 | 1 |
Loa Loa (eye worm) | low-density lipoprotein receptor repeat class B containing protein | 0.097 | 0.1634 | 0.0698 |
Echinococcus multilocularis | Tolloid protein 1 | 0.3346 | 1 | 1 |
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.1079 | 0.2017 | 0.5 |
Loa Loa (eye worm) | bone morphogenetic protein 1b | 0.3346 | 1 | 1 |
Onchocerca volvulus | Matrix metalloproteinase homolog | 0.0792 | 0.1006 | 0.616 |
Loa Loa (eye worm) | matrixin family protein | 0.0864 | 0.1258 | 0.028 |
Brugia malayi | Matrixin family protein | 0.0864 | 0.1258 | 0.6237 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.